9.00am - 4.15pm EST | 6.00am - 1.15pm PST
8:30 am Virtual Coffee & Networking
8:45 am Chairman’s Opening Remarks
9:00 am
Assessing Novel Strategies to Enhance Function in TCR-T & Drive Success in Solid Tumors
9:30 am Helping TCR-Ts Meet the Challenges of the TME
Synopsis
- Antigens/Epitopes contribute to success
- TCR sensitivity is of critical importance
- Enhanced TCR-Ts can overcome multiple hurdles
10:00 am Panel Discussion: Optimizing Development of Combination Approaches to Overcome the Solid Tumor Microenvironment
Synopsis
- Exploring how to train T cells to overcome immune defence and survive in the low-nutrient, acidic and hypoxic tumour microenvironment
- Utilizing anti-PD1 antibody fragments secreted from T-cells after tumor interaction to overcome the local suppressive environment
- Profiling metabolic TME immuno-suppressive mechanisms through use of novel technology platforms
10:30 am Adaptive Biotechnologies
Synopsis
Title to Be Confirmed
11:00 am Morning Break & Group Networking
New Frontiers in Cancer Immunotherapy: Advancing Soluble TCRs for T Cell Activation
12:00 pm Towards Safer, More Effective and Persistent T-Cell Therapies Against Solid Tumors: Targeting Intracellular Tumor Antigens with TCR-Mimic Antibody Redirected Antibody TCR (AbTCR) T-cell Therapy
Synopsis
- Targeting intracellular, tumor specific antigens by a TCR-mimic antibody (TCRm) with high affinity and specificity
- ARTEMIS® Antibody TCR (AbTCR) platform represents a novel CAR-TCR hybrid with optimal signaling strength of CAR and TCR
- Safety and efficacy validation of TCRm redirected T cells going after Alpha-fetoprotein (AFP) in advanced hepatocellular carcinoma
12:30 pm TCR Mimics as a Platform for Soluble Therapeutic Agents
Synopsis
- Monoclonal antibodies can be constructed with specificities that mimic a TCR
- The advantages and disadvantages of such platforms are described
1:00 pm Panel Discussion: Exploring the Potential of Soluble TCR Therapies to Redirect and Activate T Cells
Synopsis
- How do we enhance receptor-target interactions to develop safe and efficacious soluble TCR products?
- Beyond survival benefit, how do we define the clinical response rate to determine success in phase 3 clinical trials?
- What are the lessons that we have taken from antibodies?
1:30 pm Discovering TCRs Through Physical Reporters
Synopsis
- T-cell targets of recovering COVID-19 patients were first discovered using a high-throughput, whole-genome reporter system
- Discovery of epitope targets in solid tumors is a major limitation for immunotherapy
- TScan’s system has discovered over 40 novel, shared cancer targets to date in solid tumors
2:00 pm Lunch & Networking
Increasing Efficacy of TCRs to Optimize Next Generation Immunotherapy
3:00 pm Clinical Update: Highlighting the Outcome of a Clinical Trial with TCR-T targeting NYESO1
Synopsis
- Using small inhibitory RNA to downregulate the endogenous T cell receptors
- Clinical results of an investigator initiated in house manufactured clinical trial
- TCR T product showing efficacy targeting NYESO1
3:30 pm Exploring Novel Approaches to Reducing Manufacturing Cost and Time
Synopsis
- Maximizing T cell quality to increase efficacy, lower required cell counts and reduce the cost of manufacture
- Exploring innovative manufacturing methods during process development, to seamlessly scale up and improve processes post-approval with minimal costs
4:00 pm Chairman’s Closing Remarks
4:15 pm Close of Summit
For session details - Download Full Event Guide